FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:16-20 July 4, 1996 Number 1 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Respiratory tract infections may trigger relapses in patients with Wegener's granu-lomatosis in remission. Uncontrolled data have suggested that treatment with trimethoprim–sulfamethoxazole (co-trimoxazole) may be beneficial.

Methods We conducted a prospective, randomized, placebo-controlled study of the efficacy of co-trimoxazole (800 mg of sulfamethoxazole and 160 mg of trimethoprim) given twice daily for 24 months in preventing relapses in patients with Wegener's granulomatosis in remission during or after treatment with cyclophosphamide and prednisolone. Relapses and infections were assessed with predefined criteria based on clinical, laboratory, and histopathological findings. Patients were evaluated at least once every three months for signs of disease activity, compliance with the treatment regimen, side effects of the therapy, and evidence of infections. Titers of serum antineutrophil cytoplasmic antibodies were measured serially.

Results Forty-one patients were assigned to receive co-trimoxazole, and 40 to receive placebo. In 8 of the 41 patients in the co-trimoxazole group (20 percent), the drug had to be stopped because of side effects. According to life-table analysis, 82 percent of the patients in the co-trimoxazole group remained in remission at 24 months, as compared with 60 percent of those in the placebo group (relative risk of relapse, 0.40; 95 percent confidence interval, 0.17 to 0.98). There were fewer respiratory tract infections (P = 0.005) and non–respiratory tract infections (P = 0.05) in the co-trimoxazole group than in the placebo group. There were no significant differences in antineutrophil cytoplasmic antibody titers at any time. Proportional-hazards regression analysis identified treatment with co-trimoxazole as an independent factor associated with prolonged disease-free survival and a positive antineutrophil cytoplasmic antibody test at the start of treatment as a risk factor for relapse.

Conclusions Treatment with co-trimoxazole reduces the incidence of relapses in patients with Wegener's granulomatosis in remission.

Source Information

From the Department of Medicine, Division of Clinical Immunology (C.A.S., J.W.C.T., C.G.M.K.), and the Division of Nephrology (C.A.S., J.W.C.T., P.E.J.), University Hospital, Groningen, the Netherlands.

Address reprint requests to Dr. Stegeman at the Department of Internal Medicine, University Hospital, Oostersingel 59, 9713 EZ Groningen, the Netherlands.

Full Text of this Article

Related Letters:

Co-Trimoxazole in Wegener's Granulomatosis
Weir A., Lipman M., Congleton J., Stegeman C. A., Cohen Tervaert J. W., Kallenberg C. G.M.
Extract | Full Text  
N Engl J Med 1996; 335:1769-1770, Dec 5, 1996. Correspondence

This article has been cited by other articles:

• Gomez-Puerta, J. A., Bosch, X. (2009). Anti-Neutrophil Cytoplasmic Antibody Pathogenesis in Small-Vessel Vasculitis: An Update. Am. J. Pathol. 175: 1790-1798 [Abstract] [Full Text]  
• Gomez-Puerta, J. A., Hernandez-Rodriguez, J., Lopez-Soto, A., Bosch, X. (2009). Antineutrophil Cytoplasmic Antibody-Associated Vasculitides and Respiratory Disease. Chest 136: 1101-1111 [Abstract] [Full Text]  
• Bosch, X. (2009). LAMPs and NETs in the Pathogenesis of ANCA Vasculitis. J. Am. Soc. Nephrol. 20: 1654-1656 [Full Text]  
• Kuligowski, M. P., Kwan, R. Y. Q., Lo, C., Wong, C., James, W. G., Bourges, D., Ooi, J. D., Abeynaike, L. D., Hall, P., Kitching, A. R., Hickey, M. J. (2009). Antimyeloperoxidase antibodies rapidly induce {alpha}4-integrin-dependent glomerular neutrophil adhesion. Blood 113: 6485-6494 [Abstract] [Full Text]  
• Stassen, P M, Derks, R P H, Kallenberg, C G M, Stegeman, C A (2009). Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: relation to azathioprine maintenance treatment and adverse effects. Ann Rheum Dis 68: 758-759 [Full Text]  
• Charlier, C, Henegar, C, Launay, O, Pagnoux, C, Berezne, A, Bienvenu, B, Cohen, P, Mouthon, L, Guillevin, L (2009). Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 68: 658-663 [Abstract] [Full Text]  
• Mukhtyar, C, Guillevin, L, Cid, M C, Dasgupta, B, de Groot, K, Gross, W, Hauser, T, Hellmich, B, Jayne, D, Kallenberg, C G M, Merkel, P A, Raspe, H, Salvarani, C, Scott, D G I, Stegeman, C, Watts, R, Westman, K, Witter, J, Yazici, H, Luqmani, R, for the European Vasculitis Study Group, (2009). EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68: 310-317 [Abstract] [Full Text]  
• Pagnoux, C., Mahr, A., Hamidou, M. A., Boffa, J.-J., Ruivard, M., Ducroix, J.-P., Kyndt, X., Lifermann, F., Papo, T., Lambert, M., Le Noach, J., Khellaf, M., Merrien, D., Puechal, X., Vinzio, S., Cohen, P., Mouthon, L., Cordier, J.-F., Guillevin, L., the French Vasculitis Study Group, (2008). Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. NEJM 359: 2790-2803 [Abstract] [Full Text]  
• Mukhtyar, C, Flossmann, O, Hellmich, B, Bacon, P, Cid, M, Cohen-Tervaert, J W, Gross, W L, Guillevin, L, Jayne, D, Mahr, A, Merkel, P A, Raspe, H, Scott, D, Witter, J, Yazici, H, Luqmani, R A, on behalf of the European Vasculitis Study Group (, (2008). Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 67: 1004-1010 [Abstract] [Full Text]  
• Stassen, P. M., Sanders, J.-S. F., Kallenberg, C. G. M., Stegeman, C. A. (2008). Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 23: 654-658 [Abstract] [Full Text]  
• de Lind van Wijngaarden, R. A.F., van Rijn, L., Hagen, E. C., Watts, R. A., Gregorini, G., Tervaert, J. W. C., Mahr, A. D., Niles, J. L., de Heer, E., Bruijn, J. A., Bajema, I. M. (2008). Hypotheses on the Etiology of Antineutrophil Cytoplasmic Autoantibody Associated Vasculitis: The Cause Is Hidden, but the Result Is Known. CJASN 3: 237-252 [Abstract] [Full Text]  
• Bosch, X., Guilabert, A., Espinosa, G., Mirapeix, E. (2007). Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review. JAMA 298: 655-669 [Abstract] [Full Text]  
• Jayne, D. (2007). Leflunomide versus methotrexate in Wegener's granulomatosis. Rheumatology (Oxford) 46: 1047-1048 [Full Text]  
• Brown, H. J., Lock, H. R., Wolfs, T. G.A.M., Buurman, W. A., Sacks, S. H., Robson, M. G. (2007). Toll-Like Receptor 4 Ligation on Intrinsic Renal Cells Contributes to the Induction of Antibody-Mediated Glomerulonephritis via CXCL1 and CXCL2. J. Am. Soc. Nephrol. 18: 1732-1739 [Abstract] [Full Text]  
• Stassen, P. M, Cohen Tervaert, J. W., Stegeman, C. A (2007). Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 66: 798-802 [Abstract] [Full Text]  
• Popa, E. R., Stegeman, C. A., Abdulahad, W. H., van der Meer, B., Arends, J., Manson, W. M., Bos, N. A., Kallenberg, C. G. M., Cohen Tervaert, J.-W. (2007). Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 46: 1029-1033 [Abstract] [Full Text]  
• Hellmich, B., Flossmann, O., Gross, W. L, Bacon, P., Willem Cohen-Tervaert, J., Guillevin, L., Jayne, D., Mahr, A., Merkel, P. A, Raspe, H., Scott, D. G I, Witter, J., Yazici, H., Luqmani, R. A, on behalf of the European Vasculitis Study Group, (2007). EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66: 605-617 [Abstract] [Full Text]  
• Stewart, C., Cohen, D., Bhattacharyya, I., Scheitler, L., Riley, S., Calamia, K., Migliorati, C., Baughman, R., Langford, P., Katz, J. (2007). Oral manifestations of Wegener's granulomatosis: A report of three cases and a literature review. Journal of the American Dental Association 138: 338-348 [Abstract] [Full Text]  
• Sanders, J-S F, Huitma, M G, Kallenberg, C G M, Stegeman, C A (2006). Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. Ann Rheum Dis 65: 1484-1489 [Abstract] [Full Text]  
• Chan, B., d'Intini, V., Savige, J. (2006). Anti-neutrophil cytoplasmic antibody (ANCA)-associated microscopic polyangiitis following a suppurative wound infection. Nephrol Dial Transplant 21: 2993-2994 [Full Text]  
• Pawar, R. D., Patole, P. S., Wornle, M., Anders, H.-J. (2006). Microbial nucleic acids pay a Toll in kidney disease. Am. J. Physiol. Renal Physiol. 291: F509-F516 [Abstract] [Full Text]  
• Brown, H. J., Lock, H. R., Sacks, S. H., Robson, M. G. (2006). TLR2 Stimulation of Intrinsic Renal Cells in the Induction of Immune-Mediated Glomerulonephritis. J. Immunol. 177: 1925-1931 [Abstract] [Full Text]  
• Brown, H. J., Sacks, S. H., Robson, M. G. (2006). Toll-Like Receptor 2 Agonists Exacerbate Accelerated Nephrotoxic Nephritis. J. Am. Soc. Nephrol. 17: 1931-1939 [Abstract] [Full Text]  
• Voswinkel, J, Mueller, A, Kraemer, J A, Lamprecht, P, Herlyn, K, Holl-Ulrich, K, Feller, A C, Pitann, S, Gause, A, Gross, W L (2006). B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 65: 859-864 [Abstract] [Full Text]  
• Wolf, G., Bohlender, J., Bondeva, T., Roger, T., Thaiss, F., Wenzel, U. O. (2006). Angiotensin II Upregulates Toll-Like Receptor 4 on Mesangial Cells. J. Am. Soc. Nephrol. 17: 1585-1593 [Abstract] [Full Text]  
• Sanders, J.-S. F., Huitma, M. G., Kallenberg, C. G. M., Stegeman, C. A. (2006). Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 45: 724-729 [Abstract] [Full Text]  
• Foster, R, Rosenthal, E, Marques, S, Vounotrypidis, P, Sangle, S, D'Cruz, D (2006). Primary systemic vasculitis: treatment of difficult cases. Lupus 15: 143-147 [Abstract]  
• Frankel, S. K., Cosgrove, G. P., Fischer, A., Meehan, R. T., Brown, K. K. (2006). Update in the diagnosis and management of pulmonary vasculitis.. Chest 129: 452-465 [Abstract] [Full Text]  
• Brown, K. K. (2006). Pulmonary vasculitis.. Proc Am Thorac Soc 3: 48-57 [Abstract] [Full Text]  
• Joy, M. S., Hogan, S. L., Jennette, J. C., Falk, R. J., Nachman, P. H. (2005). A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 20: 2725-2732 [Abstract] [Full Text]  
• Hattar, K., van Burck, S., Bickenbach, A., Grandel, U., Maus, U., Lohmeyer, J., Csernok, E., Hartung, T., Seeger, W., Grimminger, F., Sibelius, U. (2005). Anti-proteinase 3 antibodies (c-ANCA) prime CD14-dependent leukocyte activation. J. Leukoc. Biol. 78: 992-1000 [Abstract] [Full Text]  
• Ioannidis, J. P. A. (2005). Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. JAMA 294: 218-228 [Abstract] [Full Text]  
• Frankel, S K, Cosgrove, G P, Brown, K K (2005). Small vessel vasculitis of the lung. Chronic Respiratory Disease 2: 75-84 [Abstract]  
• Pfister, H., Ollert, M., Frohlich, L. F., Quintanilla-Martinez, L., Colby, T. V., Specks, U., Jenne, D. E. (2004). Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104: 1411-1418 [Abstract] [Full Text]  
• Booth, A. D., Pusey, C. D., Jayne, D. R. (2004). Renal vasculitis--an update in 2004. Nephrol Dial Transplant 19: 1964-1968 [Full Text]  
• Metzler, C., Fink, C., Lamprecht, P., Gross, W. L., Reinhold-Keller, E. (2004). Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 43: 315-320 [Abstract] [Full Text]  
• Masters, P. A., O'Bryan, T. A., Zurlo, J., Miller, D. Q., Joshi, N. (2003). Trimethoprim-Sulfamethoxazole Revisited. Arch Intern Med 163: 402-410 [Abstract] [Full Text]  
• Sangle, S., Karim, Y., Hughes, G. R., D'Cruz, D. P. (2003). Reply. Rheumatology (Oxford) 42: 396-397 [Full Text]  
• Rarok, A. A., Stegeman, C. A., Limburg, P. C., Kallenberg, C. G. M. (2002). Neutrophil Membrane Expression of Proteinase 3 (PR3) Is Related to Relapse in PR3-ANCA-Associated Vasculitis. J. Am. Soc. Nephrol. 13: 2232-2238 [Abstract] [Full Text]  
• Kamesh, L., Harper, L., Savage, C. O. S. (2002). ANCA-Positive Vasculitis. J. Am. Soc. Nephrol. 13: 1953-1960 [Full Text]  
• Sangle, S., Karim, M. Y., Hughes, G. R. V., D'Cruz, D. P. (2002). Sulphamethoxazole-trimethoprim in the treatment of limited paranasal Wegener's granulomatosis. Rheumatology (Oxford) 41: 589-590 [Full Text]  
• (2001). Pulmonary nodules and splinter haemorrhages. Postgrad. Med. J. 77: 792-792 [Full Text]  
• Banerjee, A, McKane, W, Thiru, S, Farrington, K (2001). Wegener's granulomatosis presenting as acute suppurative interstitial nephritis. J. Clin. Pathol. 54: 787-789 [Abstract] [Full Text]  
• Toyoshima, M., Chida, K., Suda, T., Imokawa, S., Nakamura, H. (2001). Wegener's Granulomatosis Responding to Antituberculous Drugs. Chest 119: 643-645 [Abstract] [Full Text]  
• Auzary, C., Huong, D. l. T., Wechsler, B., Vauthier-Brouzes, D., Piette, J.-C. (2000). Pregnancy in patients with Wegener's granulomatosis: report of five cases in three women. Ann Rheum Dis 59: 800-804 [Abstract] [Full Text]  
• Jayne, D.R.W., Chapel, H., Adu, D., Misbah, S., O'Donoghue, D., Scott, D., Lockwood, C.M. (2000). Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93: 433-439 [Abstract] [Full Text]  
• Jayne, D. (2000). Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford) 39: 585-595 [Full Text]  
• SCOTT, D. G I, WATTS, R. A (2000). Systemic vasculitis: epidemiology, classification and environmental factors. Ann Rheum Dis 59: 161-163 [Full Text]  
• Watts, R. A., Scott, D. G. I., Pusey, C. D., Lockwood, C. M. (2000). Vasculitis--aims of therapy. An overview. Rheumatology (Oxford) 39: 229-232 [Full Text]  
• Nevez, G., Pruna, A., Jounieaux, V., Makdassi, R., Totet, A., Raccurt, C. (1999). A search for Pneumocystis carinii DNA by polymerase chain reaction on bronchoalveolar lavage fluids from patients with Wegener's granulomatosis. Rheumatology (Oxford) 38: 1025-1027 [Full Text]  
• NOWACK, R., GÖBEL, U., KLOOKER, P., HERGESELL, O., ANDRASSY, K., VAN DER WOUDE, F. J. (1999). Mycophenolate Mofetil for Maintenance Therapy of Wegener's Granulomatosis and Microscopic Polyangiitis: A Pilot Study in 11 Patients with RenalInvolvement. J. Am. Soc. Nephrol. 10: 1965-1971 [Abstract] [Full Text]  
• Langford, C. A, Hoffman, G. S (1999). Rare diseases bullet  3: Wegener's granulomatosis. Thorax 54: 629-637 [Full Text]  
• Kobold, A. C M., Kallenberg, C. G M, Tervaert, J. W. C. (1999). Monocyte activation in patients with Wegener's granulomatosis. Ann Rheum Dis 58: 237-245 [Abstract] [Full Text]  
• Kallenberg, C G., Heeringa, P (1998). Pathogenesis of vasculitis. Lupus 7: 280-284 [Abstract]  
• de Groot, K, Gross, W L (1998). Wegener's granulomatosis: disease course, assessment of activity and extent and treatment. Lupus 7: 285-291 [Abstract]  
• REEVES, J. T., RUBIN, L. J. (1998). The Pulmonary Circulation . Snapshots of Progress. Am. J. Respir. Crit. Care Med. 157: S101-S108 [Full Text]  
• Ledford, D. K. (1997). Immunologic Aspects of Vasculitis and Cardiovascular Disease. JAMA 278: 1962-1971 [Abstract]  
• Jennette, J. C., Falk, R. J. (1997). Small-Vessel Vasculitis. NEJM 337: 1512-1523 [Full Text]  
• Dias, B. M., Nahass, G. T. (1997). Palpable Purpura and Respiratory Failure. Arch Dermatol 133: 435-437 [Abstract]  
• Weir, A., Lipman, M., Congleton, J., Stegeman, C. A., Cohen Tervaert, J. W., Kallenberg, C. G.M. (1996). Co-Trimoxazole in Wegener's Granulomatosis. NEJM 335: 1769-1770 [Full Text]  
• (1996). TMP/SMX TO PREVENT RELAPSE IN WEGENER'S GRANULOMATOSIS. JWatch General 1996: 7-7 [Full Text]  
• DeRemee, R. A. (1996). Empiricism and Wegener's Granulomatosis. NEJM 335: 54-55 [Full Text]